Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Hideya Onishi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-4402-2555; OpenAlex author ID A5077613670. Sources: OpenAlex.

Their work

Papers
23 (first author 6, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 4 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 23

  1. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. Last author DOI 10.1016/j.surg.2026.110423↗
  2. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  3. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  4. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  5. A Novel Oncolytic Viral Therapy Using Coxsackievirus B3 (CVB3) for Human Pancreatic Cancer Including Cancer-associated Fibroblasts. Co-author DOI 10.21873/anticanres.17348↗
  6. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. First author DOI 10.7150/jca.78993↗
  7. PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15768↗
  8. TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer. Last author DOI 10.21873/anticanres.15205↗
  9. Hypoxia and pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2020.04.018↗
  10. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. First author DOI 10.1097/cji.0000000000000305↗
  11. FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients. First author DOI 10.7150/jca.38399↗
  12. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07269-z↗
  13. Liprin-α4 as a Possible New Therapeutic Target for Pancreatic Cancer. Last author DOI 10.21873/anticanres.12122↗
  14. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and … Co-author DOI 10.1002/ijc.30075↗
  15. Hypoxia but not normoxia promotes Smoothened transcription through upregulation of RBPJ and Mastermind-like 3 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.11.012↗
  16. Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. First author PMID 26851020↗
  17. Protein-bound Polysaccharide-K Inhibits Hedgehog Signaling Through Down-regulation of MAML3 and RBPJ Transcription Under Hypoxia, Suppressing the Malignant Phe… First author PMID 27466498↗
  18. Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling. First author DOI 10.1111/cas.12348↗
  19. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i9.2335↗
  20. Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1α pathways under hypoxi… Co-author DOI 10.1016/j.canlet.2013.02.041↗
  21. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2012.02297.x↗
  22. Transforming growth factor β1 contributes to the invasiveness of pancreatic ductal adenocarcinoma cells through the regulation of CD24 expression. Co-author DOI 10.1097/mpa.0b013e31821ea286↗
  23. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.01912.x↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshinao Oda · 7 shared papers, 2016–2026 · strength 1.01
  2. Kohei Nakata · 5 shared papers, 2019–2026 · strength 0.89
  3. Naoki Ikenaga · 4 shared papers, 2024–2026 · strength 0.81
  4. Akira Imaizumi · 8 shared papers, 2014–2024 · strength 0.78
  5. Masafumi Nakamura · 5 shared papers, 2019–2025 · strength 0.73
  6. Akio Yamasaki · 7 shared papers, 2016–2022 · strength 0.73
  7. Kenoki Ohuchida · 4 shared papers, 2020–2026 · strength 0.71
  8. Takashi Morisaki · 6 shared papers, 2013–2025 · strength 0.68
  9. Makoto Kawamoto · 7 shared papers, 2016–2023 · strength 0.63
  10. Toshiya Abe · 3 shared papers, 2024–2026 · strength 0.61
  11. Yasuhiro Oyama · 6 shared papers, 2016–2022 · strength 0.59
  12. Chika Iwamoto · 3 shared papers, 2024–2025 · strength 0.55
  13. Noboru Ideno · 2 shared papers, 2024–2026 · strength 0.41
  14. Mitsuo Katano · 8 shared papers, 2011–2016 · strength 0.38
  15. Chikanori Tsutsumi · 2 shared papers, 2024–2025 · strength 0.36
  16. Koki Oyama · 2 shared papers, 2024–2025 · strength 0.35
  17. Shinjiro Nagao · 2 shared papers, 2021–2023 · strength 0.27
  18. Yusuke Mizuuchi · 2 shared papers, 2016–2025 · strength 0.26
  19. Takashi Utsunomiya · 1 shared paper, 2026 · strength 0.26
  20. Masafumi Nakamura · 2 shared papers, 2020–2024 · strength 0.25
  21. Bo Zhang · 1 shared paper, 2025 · strength 0.20
  22. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.20
  23. Hisanobu Ogata · 1 shared paper, 2024 · strength 0.20
  24. Kenzaburo Tani · 1 shared paper, 2024 · strength 0.20
  25. Nao Fujimori · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.